Flex Pharma Raises $40 Million

Flex Pharma Raises $40 Million

--Top Tier Syndicate Supports Novel Treatments for Neuromuscular Disorders--

BOSTON, Sep 08, 2014 (BUSINESS WIRE) -- Flex Pharma, Inc., a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, announced today that it has raised $40 million in private funding from a number of blue chip public and private investors, including:

  • Longwood Fund
  • Bessemer Venture Partners
  • EcoR1 Capital
  • Jennison Associates LLC (on behalf of clients)
  • Lightstone Ventures
  • Alexandria Equities LLC
  • CD-Venture GmbH
  • Bindley Capital Partners LLC
  • City Hill Ventures
  • Richard Mark Beleson, retired SVP, Capital Research Company
  • Todd Dagres, Spark Capital General Partner
  • Richard Gibbs, Gibbs Capital Management
  • Daniel Gold, Managing Partner, Founder, CEO, QVT Financial LP
  • Wyc Grousbeck, Boston Celtics Managing Partner and CEO
  • Robert Steven Kaplan, Ph.D., Harvard Business School Professor
  • The Kraft Group
  • Peter S. Lynch, Trustee - The Lynch Foundation
  • John Maraganore, Ph.D., Alnylam CEO
  • Judy Pagliuca, Managing Partner, Pags Growth Capital
  • Steve Pagliuca, Bain Capital Managing Director, Boston Celtics Managing Partner
  • William Sahlman, Ph.D., Harvard Business School Professor
  • Diane and John Sculley, former Apple CEO & Sculley Family Office
  • Jonathan Seelig, Co-founder Akamai Technologies

Flex Pharma plans to further advance the science and its clinical candidates addressing neuromuscular disorders with this financing.

"We are very pleased to have Flex Pharma as part of our portfolio of investments," said Steve Kraus, Partner, Bessemer Venture Partners. "Flex Pharma's unique approach to neuromuscular disorders offers an opportunity to develop new clinical agents to address an unmet need and rapidly create value. We look forward to working with Flex Pharma's management team and our co-investors to build an exceptional new biopharmaceutical company."

"We are thrilled to partner with excellent investors, including both top-tier venture capital and leading crossover funds," said Flex Pharma Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D. "Over the past year, Flex Pharma and our scientific founders have translated fundamental new science into human efficacy. We believe the caliber of Flex Pharma's investors speaks to the strength of our science, and the hope that we may help individuals suffering from neuromuscular disorders."

"Our early stage clinical studies have shown initial human efficacy related to muscle cramping in healthy volunteers," commented Flex Pharma Co-Founder and Co-Chair of the Company's Scientific Advisory Board, Rod MacKinnon M.D., who won the 2003 Nobel Prize in Chemistry. "We are hopeful that we may be able to help individuals suffering from muscle cramps and other neuromuscular disorders."

About Flex Pharma

Flex Pharma, Inc. is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders. Flex Pharma has demonstrated initial human efficacy related to muscle cramping in healthy volunteers. The Company plans to initiate efficacy studies in patients with neuromuscular disorders in the first half of 2015.

Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate) and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D. Flex Pharma is backed by the Longwood Fund, Bessemer Venture Partners, EcoR1 Capital, Jennison Associates, LLC and a number of additional blue chip investors.

Additional information about Flex Pharma is available online at http://www.flex-pharma.com.

SOURCE: Flex Pharma, Inc.

Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
Corporate Communications & Investor Relations
[email protected]

Suggested Articles

A new, late-phase analysis of the cholesterol-lowering inclisiran showed that it was able to cut LDL levels by 51% after nearly a year-and-a-half.

The data was highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.